Zevra Therapeutics, Inc. ZVRA Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zevra Therapeutics, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zevra Therapeutics, Inc.'s accounts payable?
- Zevra Therapeutics, Inc. (ZVRA) reported accounts payable of $11.69M in Q1 2026.
- How has Zevra Therapeutics, Inc.'s accounts payable changed year-over-year?
- Zevra Therapeutics, Inc.'s accounts payable decreased by 34.4% year-over-year, from $17.82M to $11.69M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s accounts payable?
- Over 5 years (2020 to 2025), Zevra Therapeutics, Inc.'s accounts payable has grown at a 11.8% compound annual growth rate (CAGR), from $6.65M to $11.6M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.